ESR1 and breast cancer: Further, several new oral bioavailable selective estrogen receptor modulators/degraders (SERMs/SERDs), including lasfoxifene, bazedoxifene, LSZ102, and RAD1901, for ESR1 gene mutation are currently under clinical investigations to treat ESR1-mutant or endocrine therapy resistant metastatic BC (139).